The economic benefits of pharmaceutical innovations: The case of cox-2 inhibitors

Craig L. Garthwaite*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Despite dramatic improvements in medical technology, little attention has been paid to the role of these innovations in improving economic outcomes. This study estimates the labor supply effects of Cox-2 inhibitors, a widely prescribed class of pharmaceuticals used for the treatment of chronic pain and inflammation and primarily marketed under the brand names Vioxx, Celebrex, and Bextra. This paper exploits the removal of Vioxx from the market in 2004 as an exogenous change in drug use. This removal was associated with a 0.35 percentage point decrease in overall labor force participation and $19 billion in lost wages.

Original languageEnglish (US)
Pages (from-to)116-137
Number of pages22
JournalAmerican Economic Journal: Applied Economics
Volume4
Issue number3
DOIs
StatePublished - Jul 2012

ASJC Scopus subject areas

  • Economics, Econometrics and Finance(all)

Fingerprint

Dive into the research topics of 'The economic benefits of pharmaceutical innovations: The case of cox-2 inhibitors'. Together they form a unique fingerprint.

Cite this